It is “the BED [biologically
effective dose] equivalent of repopulation (in units of Gy/day)”, “the
BED-equivalent repopulation factor” [1]. It is the "increase in dose required daily to obtain same biologic effect: recommended extra dose to add to total radiation dose for each day of prolongation, which can be given by increasing daily dose of remaining treatment". "Prolongation of overall treatment time due to unplanned interruptions during radiotherapy causes deleterious effect of accelerated repopulation of tumor clonogens. For the cancers of the head and neck, even a 1-day interruption resulted in a decrease in the local control rate by 1.4%" [9]. A “K value of 0.9 Gy/day represents
the BED required each day (after Tdelay has been passed) to offset repopulation”
[2]. It is “the biological dose per day required to compensate for on-going
tumour cell repopulation. K is the BED equivalent of 1 days’ worth of
repopulation” [3], “a factor used to determine the amount of radiation ‘wasted’
due to ongoing tumour repopulation” [4]. “If chemotherapy is
able to completely inhibit repopulation then K=0 and would not be required” [1].
For head and neck treatments, it is “recommend K=0.1 Gy/day and Tdelay=0 in cases where the final overall times are less than 28 days” [1]. However, after this time, the K value is 0.5-0.7 Gy/day [9].
For head and neck treatments, it is “recommend K=0.1 Gy/day and Tdelay=0 in cases where the final overall times are less than 28 days” [1]. However, after this time, the K value is 0.5-0.7 Gy/day [9].
“There is at
present very little data relating to K and Tdelay factors for other tumour
types” [1].
“For cervix tumours, the time factors are probably around half those for head and neck tumours, i.e., 0.5 Gy/day” [1,5]. “For breast tumours, the K factors are likely to be around 0.3 Gy/day while for prostate tumours they are likely to be in the region 0.1–0.3 Gy/day, or even lower [1,6-8]”. “Little is known about the corresponding values of Tdelay” [1]. For transitional cell bladder carcinoma, K=0.36 Gy/day for a Tdelay=5-6 weeks [9]. For non-small cell lung cancer and a Tdaley>20 days, K=0.45 Gy/day [10,11]; but, for cases without mediastinal involvement, K=0.2 Gy/day [10].
“For cervix tumours, the time factors are probably around half those for head and neck tumours, i.e., 0.5 Gy/day” [1,5]. “For breast tumours, the K factors are likely to be around 0.3 Gy/day while for prostate tumours they are likely to be in the region 0.1–0.3 Gy/day, or even lower [1,6-8]”. “Little is known about the corresponding values of Tdelay” [1]. For transitional cell bladder carcinoma, K=0.36 Gy/day for a Tdelay=5-6 weeks [9]. For non-small cell lung cancer and a Tdaley>20 days, K=0.45 Gy/day [10,11]; but, for cases without mediastinal involvement, K=0.2 Gy/day [10].
Bibliographic references:
[1] Stamatakos, G. (2012). 2012 5th International Advanced
Research Workshop on In Silico Oncology and Cancer Investigation (IARWISOCI).
Piscataway, NJ: IEEE. Available at: http://www.5th-iarwisoci.iccs.ntua.gr/data/_uploaded/file/PROCEEDINGS_2012_5th_IARWISOCI_OPEN-ACCESS_VERSION_2012_DEC_05.pdf [Accessed 19 Jul. 2016].
[2] Dale RG, Hendry JH, Jones B, et al. Practical methods for compensating for missed treatment days in radiotherapy, with particularreference to head and neck schedules. Clin Oncol (R Coll Radiol). 2002 Oct;14(5):382-93. Available at: http://dx.doi.org/10.1053/clon.2002.0111.
[3] Dale RG, Jones B,
Sinclair JA. Dose-equivalents of tumour repopulation during radiotherapy: the
potential for confusion. Br J Radiol. 2000;73(872):892–894. Available at: http://dx.doi.org/10.1259/bjr.73.872.11026867.
[4] The timely delivery of radical radiotherapy: standards and guidelines for the management of unscheduled treatment interruptions. (2008). 3rd ed. London, United Kingdom: Board of Faculty of Clinical Oncology, The Royal College of Radiologists. Available at: https://www.rcr.ac.uk/sites/default/files/publication/BFCO(08)6_Interruptions.pdf [Accessed 17 Jul. 2016].
[5] Hendry JH, Bentzen
SM, Dale RG, et al. A modelled comparison of the effect of using different ways
to compensate for missed treatment days in radiotherapy. Clin Oncol. 1996;8(5):297–307. Available at: http://dx.doi.org/10.1016/s0936-6555(05)80715-0.
[6] Haustermans K,
Fowler J, Geboes K, et al. Relationship between potential doubling time (Tpot),
labelling index and duration of DNA synthesis in 60 oesophageal and 35 breast
tumours: is it worthwhile to measure Tpot? Radiother Oncol. 1998;46(2):157–167. Available at: http://dx.doi.org/10.1016/s0167-8140(97)00164-3.
[7] Trott KR,
Kummermehr J. What is known about tumour proliferation rates to choose between
accelerated fractionation or hyperfractionation? Radiother Oncol. 1985;3(1):1–9. Available at: http://dx.doi.org/10.1016/s0167-8140(85)80002-5.
[8] King CR. What is
the Tpot for prostate cancer? Radiobiological implications of the equivalent
outcome with 125I or 103Pd. Int J Radiat Oncol Biol Phys. 2000;47(5):1165–1167. Available at: http://dx.doi.org/10.1016/s0360-3016(00)00543-5.
[9] Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61. Available at: http://dx.doi.org/10.1016/j.ijrobp.2007.03.010.
[10] Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):315-22. Available at: http://dx.doi.org/10.1016/0360-3016(95)02102-7.
[11] Chen M, Jiang GL, Fu XL, et al. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer. 2000 Apr;28(1):11-9. Available at: http://dx.doi.org/10.1016/S0169-5002(99)00113-0.
[9] Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):654-61. Available at: http://dx.doi.org/10.1016/j.ijrobp.2007.03.010.
[10] Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):315-22. Available at: http://dx.doi.org/10.1016/0360-3016(95)02102-7.
[11] Chen M, Jiang GL, Fu XL, et al. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer. 2000 Apr;28(1):11-9. Available at: http://dx.doi.org/10.1016/S0169-5002(99)00113-0.
God bless Dr. USELU for his marvelous work in my life, I was diagnosed of HERPES SIMPLEX VIRUS since 2018 and I was taking my medications, I wasn't satisfied i needed to get the HERPES out of my system, I searched about some possible cure for HERPES i saw a comment about Dr. USELU , how he cured HERPES with his herbal medicine, I contacted him and he guided me. I asked for solutions, he started the remedy for my health, he sent me the medicine within 3 days. I took the medicine as prescribed by him and 2 weeks later i was cured from HERPES contact him via email (dr.uselucaregiver@gmail.com) once again thanks to you Dr. USELU cure the flowing virus, contact his email or add him on whatsapp (+2349019328641) cancer cure
ReplyDeletediabetes cure
ringing ear
herpes cure
warts cure
HPV cure
HIV cure
get your ex back
pregnancy herbal medicine
Hepatitis